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Abstract: 
This study demonstrates continuous enantiomeric inversion and further biotransformation of 
chiral profens including ibuprofen, naproxen and ketoprofen by an enzymatic membrane 
bioreactor (EMBR). The EMBR dosed with laccase showed non-enantioselective 
transformations, with high and consistent transformation of both (R)- and (S)-ibuprofen (93 ± 6 
%, n=10), but lower removals of both enantiomers of naproxen (46 ± 16 %, n=10) and 
ketoprofen (48 ± 17 %, n=10). Enantiomeric analysis revealed a bidirectional but uneven 
inversion of the profens, for example 14% inversion of (R)- to (S)- compared to 4% from (S)- to 
(R)-naproxen. With redox-mediator addition, the enzymatic chiral inversion of both (R)-/(S)-
profens remained unchanged, although the overall conversion became enantioselective:  except 
for (S)-naproxen, the addition of redox mediator promoted the degradation of (R)-profens only.  
Keywords: biotransformation; chiral pharmaceuticals; enzymatic membrane bioreactor; 
enantiomeric inversion; enantioselective; redox-mediator 
 
1. Introduction 
Pharmaceuticals are continuously released into the environment from households, animal 
husbandries, aquacultures, and the pharmaceutical manufacturing industry either in 
unmetabolized or partially metabolized forms (Mompelat et al., 2009). They eventually end up in 
wastewater and aquatic environment in the concentrations of a few ng/L to several µg/L (Hai et 
al., 2014; Luo et al., 2014; Tran et al., 2013). More than 50% of pharmaceuticals are chiral. In 
other words, they exist as either (R)- or (S)-enantiomers (Khan, 2014; Nguyen et al., 2006). 
Although chiral compounds have similar physical and chemical properties, the biodegradability 
and toxicity of enantiomers can differ significantly (Khan, 2014; MacLeod et al., 2007; Nguyen 
et al., 2006). For instance,  biotransformation of (S)- ibuprofen was faster  than (R)- ibuprofen in 
a constructed wetland (Hijosa-Valsero et al., 2010). (S)-enantiomer of  ibuprofen, naproxen, and 
propranolol had higher rates of biotransformation  than the corresponding (R)- enantiomers in an 
aerobic wastewater treatment plant (Fono & Sedlak, 2005). The toxic effects of fluoxetine, a 
chiral pharmaceutical widely used for treatment of depression, are enantiomer-dependent with 
(S)- exhibiting greater toxicity to Pimephales promelas than (R)- fluoxetine (MacLeod et al., 
2007).  
When assessing the effectiveness of wastewater treatment systems, most studies have monitored 
the removal of racemic mixtures without consideration of their enantiomeric forms (Luo et al., 
2014) . Only a few studies attempted to observe chiral inversion using pure enantiomer (Hashim 
et al., 2011; Kasprzyk-Hordern & Baker, 2011). However, those studies have tended to highlight 
the preferential degradation of one enantiomer (e.g., (S)- over (R)- ibuprofen, and (R)- over (S)-
ketoprofen).  
An enzymatic membrane bioreactor (EMBR) combines enzymatic treatment and ultrafiltration to 
completely retain the enzymes within the reactor and enable enzyme replenishment during 
continuous operation (Ji et al., 2016; Modin et al., 2014). Among the oxidoreductase enzymes, 
laccases (E.C. 1.10.3.2) have received much attention due to their capacity to degrade phenolic 
and certain non-phenolic compounds. An EMBR dosed with laccase was reported to remove a 
broad spectrum of pharmaceuticals that are resistant to conventional biological processes 
(Nguyen et al., 2015). The degradation efficiency and substrate spectrum of laccase can be 
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enhanced by the addition of redox mediators, which form reactive radicals upon oxidation by 
laccase. The reactive radicals act as “electron shuttles” between laccase and the substrate, thus 
overcoming any effects of  steric hindrance  (Yang et al., 2013).  
Laccase and mediators have been used in the pharmaceutical industry, for example, as a mild aid 
in the deracemization process to synthesize pure enantiomers (Diaz-Rodriguez et al., 2015; 
Galletti et al., 2014). Diaz-Rodriguez et al. (2015) used laccase and the mediator 2,2,6,6-
tetramethylpiperidin-1-yloxy in the first step of deracemization of racemic 2-phenyl-1-propanol. 
A  laboratory-scale multiphase hollow fiber membrane reactor was employed to produce 
optically pure butyrate by the lipase-catalyzed reaction of racemic glycidyl butyrate (Wu et al., 
1993). However, enzymatic chiral inversion and further transformation of pharmaceuticals in 
water have not been investigated yet.    
This study investigates the fate of three chiral pharmaceuticals (“profens”), namely ibuprofen, 
naproxen and ketoprofen during EMBR treatment. Pure (R)- and (S)-enantiomers were used to 
facilitate the observation of chiral inversion. A preliminary assessment of enantiomeric 
transformation of the compounds by laccase was performed in a series of batch tests. This was 
followed by long-term observation of the fate of the profens during continuous treatment by an 
EMBR. The impact of addition of a redox mediator, 1-hydroxybenzotriazole (HBT), on the 
enzymatic transformation of the profens in the EMBR was also evaluated. Overall, this study 
provides unique insight into the fate of chiral pharmaceuticals at an enantiomeric level.  
2. Materials and methods 
2.1 Crude laccase preparation 
Crude laccase solution was collected from the culture of white-rot fungi Pleurotus ostreatus 
(ATCC 34675) grown in malt extract broth (2 g/L) (Merck, Germany). The fungi were incubated 
under sterile conditions on a rotary shaker at 70 rpm and 28 °C. After 3 days of incubation, the 
crude enzyme solution (i.e., the liquid portion of the culture) was extracted and stored at 4 °C. 
The laccase activity in crude enzyme solution was 50-60 µM(DMP)/min (measured using 2.6-
dimethoxyl phenol (DMP) as substrate).  
To allow EMBR operation with nominal addition of laccase, the crude enzyme solution was 
concentrated at a volumetric ratio of 20:1 using a spiral wound, tangential flow filtration 
membrane module (Merck Millipore, Australia) with a molecular weight cutoff of 1 kDa and 
surface area of 0.23 m2. The crude laccase solution was recirculated through the membrane at a 
cross-flow velocity of 0.007 m/s. The retentate was returned to the enzyme container, and the 
permeate was discarded. The final solution showed an activity of 500µM(DMP)/min, which is less 
than that expected based on the 20:1 concentration ratio. It was confirmed that the membrane 
effectively retained laccase (40 kDa) i.e., no enzyme activity was detected in the membrane 
permeate, however, laccase denaturation may have occurred due to shear stress during the 
filtration process (Ji et al., 2016; Modin et al., 2014).   
2.2 Chemicals 
Pure (R)- and (S)-enantiomers of ibuprofen, naproxen, and ketoprofen (Supplementary Data 
Table S1) and the redox mediator 1-hydroxybenzotriazole (HBT) were purchased from Sigma-
Aldrich (Australia). The profens were dissolved in pure methanol to make up stock solutions of 
4 
 
0.2 g/L each and stored at -18 °C until use. HBT was dissolved in Milli-Q water to make up a 
stock solution of 50 mM and stored at 4 °C.  
2.3 Batch tests 
A crude enzyme solution with an initial laccase activity of 50 µM(DMP)/min was used for the 
batch tests.  Profens were incubated with the crude enzyme with a nominal concentration of 5 
µg/L for each compound (actual concentrations were in the range of 1 to 3 µg/L). The first set 
contained only the R- enantiomers. Similarly, the second set contained (S)-profens and the final 
set included the racemic form of the compounds. All the beakers were covered with aluminium 
foil and incubated in a rotary shaker at 70 rpm and 28 °C (Bioline Shaker Incubator BL 8600, 
Edwards Group Pty. Ltd, NSW, Australia). The samples were collected at the intervals of 4, 8, 
12, 24, and 48 h for profen analysis. Control samples containing only profens in Milli-Q water 
were incubated in parallel. The whole test medium was diluted to 500 mL with Milli-Q water 
and filtered through 0.45 µm glass fibre filter (Filtech, Australia). All samples were then spiked 
with a standard solution of isotopically labelled versions of each analyte (50 ng) for isotope 
dilution quantitation. The samples were loaded to SPE cartridges under vacuum and maintained 
with a constant flow rate of 15 mL/min, rinsed with 5 mL Milli-Q water, and finally dried under 
a gentle nitrogen gas flow for 30 min. The samples were then analyzed by GC-MS/MS (see 
Section 2.5.2).  
2.4 Enzymatic membrane reactor design and operation protocol 
A laboratory scale EMBR system consisting of a 0.8 L (active volume) glass reactor was used 
(Supplementary Data Figure S2). A hollow fiber ultrafiltration (UF) membrane module made of 
polyacrylonitrile was submerged in the reactor. The membrane was supplied by Microza 
Membrane (Pall Corporation, NSW, Australia) and had a MWCO, surface area and clean water 
flux of 3 kDa, 0.2 m
2
 and 25 L/h bar, respectively. The membrane was operated at a flux of 0.5 
L/m
2
 h via a peristaltic pump (Masterflex L/S, USA) with 8 min on and 1 min off cycles. The 
reactor was placed in a water bath with a temperature controller unit (Julabo, Germany) to 
maintain the temperature at 28 °C. Dissolved oxygen concentration was maintained at 3 mg/L 
via an air pump (ACO-002, Zhejiang Sensen Industry Co. Ltd., Zhejiang, China) connected to a 
stone diffuser at the bottom of the reactor. The pH of the reactor supernatant remained at 5.6 ± 
0.2 (n=16) without any specific control. The EMBR was operated at a hydraulic retention time 
of 8 h. Transmembrane pressure (TMP) was continuously monitored using a high-resolution 
(±0.1 kPa) pressure sensor (SPER scientific 840064, Extech Equipment Pty. Ltd, Victoria, 
Australia) connected to a computer for data logging.  
The EMBR was first operated to confirm retention of the enzyme and the stability of enzymatic 
activity under the applied hydraulic conditions in this study. Crude laccase solution (12 mL) was 
diluted to a final volume of 0.8 L in the reactor by Milli-Q water to obtain an initial enzymatic 
activity of 50 µM(DMP)/min. Enzymatic activity in the permeate and supernatant was measured 
every 5 h to confirm that the membrane effectively retained the enzyme (i.e., no laccase activity 
was observed in the permeate). In addition to enzyme retention, the maintenance of enzymatic 
activity level during the EMBR operation is an important factor. Denaturation of enzyme due to 
various factors including physical, chemical and biological inhibitors and the effect of shear 
stress during filtration has been reported in the literature (Mendoza et al., 2011). In this study, the 
enzymatic activity was maintained stable at 50 µM(DMP)/min within the reactor by addition of 
concentrated crude laccase solution at 0.8 % of the reactor volume every 12 h.  
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The EMBR was then operated to investigate enantiomeric transformation for around 72 days 
(i.e., 18 days each for EMBR-(R)-profens, EMBR-(S)-profens, EMBR-(R)-profens with HBT, 
and EMBR-(S)-profens with HBT). A synthetic wastewater (i.e., profens in ultrapure water) was 
used to precisely assess the enzymatic conversion of the profens by the EMBR. The next 
experiment will involve the use of real wastewater, the effect of other operating parameters such 
as enzyme loading, initial profens concentrations, pH). In all experiments, each profen was 
added at an initial concentration of approximately 2.5 µg/L (actual measured concentrations of 
2.1 ± 0.2 µg/L (R)-ibuprofen, 2.2 ± 0.2 µg/L (R)-naproxen, 2.8 ± 0.1 µg/L (R)-ketoprofen, 2.4 ± 
0.1 µg/L (S)-ibuprofen, 2.4 ± 0.1 µg/L (S)-naproxen, and 2.7 ± 0.1 µg/L (S)-ketoprofen, n= 20). 
The concentration was selected based on the commonly reported concentration of profens in 
municipal wastewater. HBT was added continuously via a peristaltic pump at a flow rate of 0.5 
mL/min to achieve a mediator concentration of 10 µM in the reactor. Following each operation 
regime, the EMBR supernatant was discarded and the UF membrane was subjected to 
backwashing with 1 L Milli-Q water at a flux of 5 L/m
2
 h. The subsequent operation regime 
commenced with freshly introduced test solution to the reactor.  Although the feed contained 
either (R)- or (S)-profen, the concentration of both (R)- and (S)-profens in the permeate of the 
EMBR was monitored to calculate the removal efficiency and quantify any chiral inversion.  
2.5 Analytical methods 
2.5.1 Enzyme assay 
Laccase activity was determined by monitoring the oxidation of 10 mM DMP in 100 mM 
sodium citrate buffer solution (pH 4.5) over 2 min at room temperature. The measurement was 
based on monitoring the change in absorbance at a wavelength of 468 nm by a 
spectrophotometer (UV-Visible UV-1700, Shimadzu, Kyoto, Japan). Laccase activity was 
calculated from the molar extinction coefficient ε = 49.6/mM.cm and expressed in µM(DMP)/min.  
2.5.2 Chiral pharmaceutical analysis 
The method used for GC-MS/MS analysis has been previously described and validated (Hashim 
& Khan, 2011). Briefly, the enantioseparations of analytes were performed on a HP5-MS fused 
silica capillary column (30 m x 0.25 mm I.D. x 0.25 µm film thickness) with 0.8 mL/min helium 
flow. The injector, interface and source temperature were 270, 260 and 280 °C, respectively. 
Samples were injected (1 µL) in splitless mode with a purge delay of 1 min. GC oven 
temperature was programmed initially at 120 ºC for 1 min, then increased by 40 °C per min to 
240 ºC and finally by 5 °C per min to 300 ºC and maintained for 4 min. The total run time was 
18 min per sample. The quantitative detection limit of this analytical method was 5 ng/L. The 
removal of (R)- and (S)-profens was calculated using Equation 1 and 2. 
Removal	efficiency	of	enantiomer	% 	=
 −	

× 100 Equation 1 
Removal	efficiency	of	enantiomer	% 	=
 −	

× 100 Equation 2 
Where; RF and SF is the concentration of (R)- and (S)-enantiomer in the feed and RP and SP is the 
concentration of (R)- and (S)-enantiomer in the permeate.  
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The relative concentration of enantiomers of the chiral compounds was expressed as the 
enantiomeric fraction (EF). The EF of the feed was calculated using Equation 3 and 4 where the 
feed contained (R)-enantiomer and (S)-enantiomer, respectively.   
		 = 	

 + 
 Equation 3 
 =	

 + 
  Equation 4 
The same calculations were used to calculate EF for the permeate as the feed.  
For enantiomerically pure starting materials EF equals 1 and in that case reduction in EF 
following treatment can be used to identify chiral inversion. 
The Student’s t-test was performed to verify if the removal efficiency of the enantiomers of a 
specific compound was statistically different (i.e., p value < 0.05).   
3. Results and discussion 
3.1 Laccase degradation of profens in batch experiments 
[FIGURE 1] 
The removal of an enantiomer (i.e., disappearance of the parent molecule) implies its chiral 
inversion and/or transformation to other metabolites. Figure 1 presents the removal of profens in 
the batch mode after 8 h of incubation. Under the laccase dose of 50 µM(DMP)/min and profen 
loading of 5 µg/L, the removals of all profens were below 30%. No improvement in the removal 
efficiency was observed when the incubation time was increased to 48 h (Figure 2). This is 
consistent with previous reports regarding batch enzymatic degradation systems where 
degradation products may interfere with further enzymatic degradation of the parent compound 
(Cajthaml, 2015; Tauber et al., 2005).  More importantly, as indicated by EF, no significant 
chiral inversion was observed in batch experiments (Figure 1). In other words, the pure 
enantiomers were oxidized mainly to other metabolites than the opposite enantiomer.  Possible 
metabolites of profens were not analyzed in this study, however, these can be identified from the 
relevant literature. For example, 1-hydroxyibuprofen, 1,2-dihydroxyibuprofen and  2-
hydroxyibuprofen are known metabolites from laccase  treatment of racemic ibuprofen (Marco-
Urrea et al., 2009). Notably, additional batch tests with racemic solutions showed a change in EF 
for naproxen (Figure 2). Because the pure enantiomers did not show chiral inversion in the batch 
tests, this change in EF of the racemic solution following enzymatic treatment does not mean 
chiral inversion, rather it implies different biodegradation rates for the (R) and (S) enantiomers.  
 [FIGURE 2] 
Overall, the batch tests with pure enantiomers demonstrated that the laccase used in this study 
could oxidize both (R)- and (S)-profens without any apparent chiral inversion or variability in 
removal rates. However, the reaction dynamics in a continuous flow EMBR are different from 
the batch test conditions. For example, in an EMBR, degradation products are continually 
removed from the reaction site. Indeed, Nguyen et al. (2015) demonstrated that an enzyme gel 
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layer formed on membrane retained pharmaceuticals and thus facilitated their degradation. Thus, 
further investigations with continuous flow EMBRs were conducted and the results are discussed 
in the following sections.  
 
3.2 Removal of profens by EMBR 
Figure 3 shows the removal efficiency of (R)- and (S)-profens during continuous treatment. 
Similar removal (i.e., either chiral inversion and/or transformation to other products) was 
observed for (R)- and (S)- ibuprofen (90 ± 5 and 93 ± 6 % (n= 10) removal, respectively). The 
ibuprofen removal observed in the current study is almost 20% higher than that in a previous 
study (Nguyen et al., 2015) where racemic ibuprofen instead of pure enantiomers was used. It is 
possible that the low removal of racemic ibuprofen in the previous study (Nguyen et al., 2015) 
was due to the competition of the two enantiomers for the active sites of laccase, or the inhibition 
of one enantiomer for the enzyme for which the other enantiomer is a substrate (Kasprzyk-
Hordern & Baker, 2011). However, this cannot be confirmed because in addition to the 
difference in feed (racemic mixture vs. pure enantiomers) a different laccase preparation was 
used in the previous study. The high removal of ibuprofen in this study was comparable with the 
reported data by other processes such as membrane bioreactors and white-rot fungi treatment. 
Hashim et al. (2011) obtained above 90% removal of ibuprofen by membrane bioreactors. A 
complete removal of ibuprofen was reported in (Marco-Urrea et al., 2009). However, the 
removal in those studies was analyzed as the sum of two enantiomers in influent and effluent.   
Compared to the high and consistent transformation of both (R)- and (S)-ibuprofen (93 ± 6 %, 
n=10), lower removals of both enantiomers of naproxen (46 ± 16 %, n=10) and ketoprofen (48 ± 
17 %, n=10) were observed. This observation is consistent with previous studies confirming 
higher resistance of naproxen and ketoprofen to enzymatic degradation compared to ibuprofen 
(Nguyen et al., 2015). Nguyen et al. (2015) reported that racemic naproxen and  ketoprofen were 
resistant to EMBR treatment possibly due to the presence of the carboxylic group (-COOH), 
which is an electron demanding functional group. A moderate removal of ketoprofen and 
naproxen also been reported in various study employed bacteria or fungi (Hashim et al., 2011; 
Luo et al., 2014).     
Compared to the batch tests (Figure 1), the EMBR showed a better removal efficiency of all 
profens (Figure 3). The higher removal of the profens by the EMBR may be due to retention of 
profens by a dynamically formed enzyme gel layer on the membrane, which may have facilitated 
further degradation. During the filtration process the enzyme can form a thin gel layer on the 
membrane (Modin et al., 2014). This thin enzyme gel layer may adsorb or retain the pollutants in 
the reactor and degrade them further as demonstrated in a previous EMBR study (Nguyen et al., 
2015), which, however, investigated racemic mixtures of profens, not their pure enantiomers.   
Enantioselective degradation i.e., preferential degradation of one enantiomer over the other has 
been reported in previous studies, where racemic mixtures were used (Hanlon et al., 1994; Hung 
et al., 1996). For example, Hanlon et al. (1994) reported that the fungus Verticillium  lecanii 
degraded (R)-ibuprofen  selectively when they used racemic ibuprofen. On the other hand, 
Hashim et al. (2011) observed preferential degradation of (S)-ibuprofen by conventional 
activated sludge. Enantioselective  degradation of chiral pharmaceuticals in the wastewater 
treatment plants can lead to the accumulation of certain enantiomers in the environment (Hashim 
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et al., 2010). The results of this study confirm that laccase degrades both (R) and (S) profens with 
similar efficiencies 
It is noted that to date the EMBR technology has not been well tested using real wastewater. So 
far, only one study successfully operated an EMBR for 100 h with minimal repetitive addition of 
enzyme for the removal of estrogenic compounds from filtered secondary effluent (Lloret et al., 
2013). The physical and chemical properties of the wastewater to be treated could adversely 
affect the enzymatic activity, stability and substrate specificity of the enzyme. These properties 
are important in process design and optimization of the enzyme treatment process and scale-up 
into pilot and full scale application. However, these features are beyond the scope of current 
study. This study confirms that laccase degrades both (R)- and (S)-profens with similar 
efficiencies which can be an important implication in propelling further studies on the above-
mentioned parameters.  
  
 [FIGURE 3] 
3.3 Chiral inversion of profens in EMBR 
The test solutions of (R)- and (S)-profens showed an EF of 0.99, indicating only trace impurities. 
Any decrease in EF during the EMBR treatment would indicate chiral inversion (Equation 3 and 
4). The concentrations of (R)- and (S)-profens and the EF in the permeate of the EMBR at 
different sampling events (Figure 4) illustrated a compound-specific bidirectional inversion of 
the chiral pharmaceuticals. This appears to be the first evidence of the bidirectional inversion of 
the tested profens i.e., ibuprofen, naproxen and ketoprofen. Previous studies have mostly 
reported unidirectional inversion of profens by microbes (Hashim et al., 2011; Hashim et al., 
2010; Hutt et al., 1993).  
[FIGURE 4] 
The EF of ibuprofen in the permeate was 0.82 ± 0.03 and 0.75 ± 0.04 (n = 10), when the feed 
contained (R)-ibuprofen and (S)-ibuprofen, respectively. The concentrations of (R)- and (S)- 
enantiomer in the permeate was quantified and calculated to be less than 2% of initial (S)- or (R)- 
enantiomer, respectively. This is low compared to the overall removal of over 90% of ibuprofen, 
meaning that ibuprofen was predominantly biotransformed to other metabolites.  
The EF of naproxen in the EMBR permeate was determined to be 0.74 ± 0.02 and 0.92 ± 0.01, (n 
= 10), when the feed contained (R)- and (S)- naproxen, respectively, confirming greater 
inversion of (R)- to (S)-naproxen. Compared to 46 ± 18 and 46 ± 13% overall removal of (R)- 
and (S)-naproxen (Figure 3), respectively, 14 ± 4 % of (R)-naproxen in the influent was inverted 
to (S)-enantiomer, while only 4 ± 1 % of (S)-naproxen was inverted to (R)-naproxen (Figure 4). 
The mode of enantiomeric inversion of naproxen by fungal laccase in this study appears to be 
somewhat different from that by bacteria. For example, a significant increase of (R)-naproxen in 
treated effluent was noticed after treatment of a synthetic wastewater containing (S)-naproxen by 
bacteria-dominated activated sludge (Hashim et al., 2011).  
A minor change in the EF of ketoprofen was observed when the EMBRs were fed with its (R)- or 
(S)-enantiomers, confirming minimal chiral inversion (Figure 4) and non-enantioselective 
biodegradation (Figure 3). Indeed ketoprofen is widely administered as a racemic mixture, and 
minimal enantioselectivity during human metabolism has been reported (Jamali & Brocks, 
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1990). Hashim et al. (2011) also observed no significant change in EF of ketoprofen during 
treatment by bacteria-dominated activated sludge.  
3.4 Impact of redox mediator dosing  
In previous studies, laccase-mediator systems have been demonstrated to enhance the removal 
efficiency of pharmaceuticals (Nguyen et al., 2014; Yang et al., 2013). Two factors contribute to 
the enhanced performance of the mediator-amended enzyme systems  i) reduction of steric 
hindrance, and ii) higher redox potential of the hydroxyl radicals generated (Yang et al., 2013). 
As shown in Figure 5, in this study, HBT addition consistently improved the removal of (R)-
profens: an improvement of 10 to over 30% was achieved (p < 0.05, Table 1). However, HBT 
addition had no effect on the chiral inversion of (R)- profens. Apparently, the radicals which are 
produced via oxidation of HBT by laccase could easily attack the (R)-enantiomers. Indeed 
Tanaka et al. (2001) reported that the addition of mediator hydroquinone to a reactor containing 
the yeast Trichosporon cutaneum was effective for the degradation of (R)-ibuprofen and the 
repression of (S)-ibuprofen degradation. Tanaka et al. (2001) explained that hydroquinone may 
have had inhibited mono- or dioxygenase enzymes which were essential for initial degradation of 
(S)-ibuprofen.   
[FIGURE 5] 
 [TABLE 1] 
In this study, except for (S)-naproxen, the removal of (S)-profens remained unaffected by HBT 
addition. Additionally, HBT addition showed negligible impact on the conversion of (S)- to (R)-
profens.  This observation indicates that with HBT addition, degradation to other metabolites 
proceeds preferentially over enantiomeric inversion. This is probably because hydroxyl radicals 
generated by the laccase-HBT system promoted profen degradation.   
It is noteworthy that operating parameters such as pH, enzyme loading, temperature, profens 
concentrations, and the presence of wastewater-derived inhibitory compounds would have 
impact on the performance of the EMBR system. The effects of these parameters on the 
enzymatic degradation of micropollutants have been generally studied (Lloret et al., 2010; Wen 
et al., 2010; Zhang & Geißen, 2010) . However, there has been no study about the impact of 
these parameters on the enzymatic degradation of profens at enantiomeric level. This is the first 
study on the enzymatic chiral inversion and further transformation of pharmaceuticals in water. 
Future studies specifically focusing on the impact of relevant operating parameters on EMBR 
performance are recommended.  
4. Conclusion 
Enantiomeric inversion and further degradation of profens by an EMBR was investigated for the 
first time. Bidirectional inversion of the chiral pharmaceuticals, particularly for naproxen was 
observed. Overall profen degradation was non-enantioselective, with high and consistent 
removal of both (R)- and (S)-ibuprofen but relatively lower levels of removal of the enantiomers 
of naproxen and ketoprofen. The influence of redox mediator on the enzymatic degradation of 
some profens appeared to be enantioselective. The addition of redox mediator promoted the 
degradation of (R)-profens mainly, while showing no impact on chiral inversion.  
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List of figures: 
Figure 1: Removal of (R)- and (S)-profens and enantiomeric fraction (EF) of profens following 
laccase treatment over 8 h in batch test conditions. The error bars represent the standard 
deviation (n=10). 
Figure 2: Concentration of the enantiomers and enantiomeric fraction (EF) after treatment of 
enantiomerically pure and racemic profen solutions with laccase in batch tests at different 
incubation time. Change in EF in the racemic naproxen solution is notable. The error bars 
represent the standard deviation (n=10). 
Figure 3: Removal efficiency of the profens by EMBR. EMBRs were fed with (R)- and (S)-
profens separately and operated at a hydraulic retention time of 8 h. The error bars represent the 
standard deviation (n=10). 
Figure 4: The concentration of (R)- and (S)-enantiomers in the EMBR feed and permeate, and 
enantiomeric fractions (EF) of the profens in the permeate, showing chiral conversion.  For the 
EMBR receiving (R)-profens, the EF was calculated by (R)/[(R) + (S)] and the EF in the influent 
was 0.99 ± 0.01 (n=10). For the EMBR receiving (S)-profens, the EF was calculated by (S)/[(R) 
+ (S)] and the EF in the influent was 0.99 ± 0.01 (n=10). 
Figure 5: The concentration of (R)- and (S)-profens in feed and permeate from separate EMBR 
experiments with and without redox-mediator (i.e., HBT) addition. The error bars represent the 
standard deviation (n=10). NQ: non-quantifiable. 
 
 
 
 
 
 
 
 
 
 
 
14 
 
(R
)-
ib
u
p
ro
fe
n
(S
)-
ib
u
p
ro
fe
n
(R
)-
n
ap
ro
x
en
(S
)-
n
ap
ro
x
en
(R
)-
k
et
o
p
ro
fe
n
(S
)-
k
et
o
p
ro
fe
n
0
10
20
30
40
50
60
70
80
90
100
 
 Removal efficiency (%)
0.0
0.2
0.4
0.6
0.8
1.0
R
em
o
v
al
 e
ff
ic
ie
n
cy
 (
%
)
 EF
 
E
n
an
ti
o
m
er
ic
 f
ra
ct
io
n
 (
E
F
)
 
 
Figure 1: Removal of (R)- and (S)-profens and enantiomeric fraction (EF) of profens following 
laccase treatment over 8 h in batch test conditions. The error bars represent the standard 
deviation (n=10). 
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Figure 2: Concentration of the enantiomers and enantiomeric fraction (EF) after treatment of 
enantiomerically pure and racemic profen solutions with laccase in batch tests at different 
incubation time. Change in EF in the racemic naproxen solution is notable. The error bars 
represent the standard deviation (n=10). 
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Figure 3: Removal efficiency of the profens by EMBR. EMBRs were fed with (R)- and (S)-
profens separately and operated at a hydraulic retention time of 8 h. The error bars represent the 
standard deviation (n=10). 
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Figure 4: The concentration of (R)- and (S)-enantiomers in the EMBR feed and permeate, and 
enantiomeric fractions (EF) of the profens in the permeate, showing chiral conversion.  For the 
EMBR receiving (R)-profens, the EF was calculated by (R)/[(R) + (S)] and the EF in the influent 
was 0.99 ± 0.01 (n=10). For the EMBR receiving (S)-profens, the EF was calculated by (S)/[(R) 
+ (S)] and the EF in the influent was 0.99 ± 0.01 (n=10). 
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Figure 5: The concentration of (R)- and (S)-profens in feed and permeate from separate EMBR 
experiments with and without redox-mediator (i.e., HBT) addition. The error bars represent the 
standard deviation (n=10). NQ: non-quantifiable. 
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Table 1: Statistical analysis of removal data  
 
Compounds 
EMBR-(R) profens 
vs 
EMBR-(S) profens 
EMBR-(R) profens with  
vs 
without HBT 
EMBR-(S) profens with  
vs 
without HBT 
 P value P value P value 
Ibuprofen 0.492 0.008 0.105 
Naproxen 0.930 0.027 0.479 
Ketoprofen 0.652 0.023 NQ 
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Table S1: Physicochemical properties of the selected pharmaceuticals 
  Molecular structure 
Compounds 
 
Molecular 
weight 
(g/mol) 
(R)-enantiomer (S)-enantiomer 
Ibuprofen 
(C13H18O2) 
(5687-27-1) 
206.28 
 
COOH
HH3C
H3C
CH3  
Naproxen 
(C14H14O3) 
(22204-53-1) 
230.26 
  
Ketoprofen 
(C16H14O3) 
(22071-15-4) 
254.28 
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Figure S2: Schematic of an enzymatic membrane reactor utilized in this study.  
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